Herbal Medicinal Products Department, CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow, India.
Division of Endocrinology, CSIR-Central Drug Research Institute, Lucknow, India.
Med Res Rev. 2018 Sep;38(6):2024-2057. doi: 10.1002/med.21504. Epub 2018 May 7.
With an increase in the ageing population worldwide, the prevalence of osteoporosis increases at an alarming rate in both male and female irrespective of their ethnicity. At present, the currently available therapeutic options are mostly limited to either bone resorptive or bone forming efficacies and both approaches are associated with serious side effects. Despite these options, there is still need for newer therapeutics to treat osteoporosis, which can offer beneficial effects for maintaining balanced dynamics between bone formation and bone resorption, devoid of any side effect. The proper understanding of pathophysiology of the disease is essential for designing or investigating an effective and safe anti-osteoporotic agent. This review represents a discussion around the molecular targets with their implications in disease progression, available therapeutic options, the emerging targets, and the importance of designing an effective anti-osteoporotic agent.
随着全球人口老龄化的增加，无论其种族如何，男性和女性的骨质疏松症患病率都以惊人的速度增长。目前，可用的治疗选择大多仅限于骨吸收或骨形成的疗效，这两种方法都与严重的副作用有关。尽管有这些选择，但仍需要新的治疗方法来治疗骨质疏松症，这种治疗方法可以提供有益的效果，以维持骨形成和骨吸收之间的平衡动态，而没有任何副作用。正确理解疾病的病理生理学对于设计或研究有效的、安全的抗骨质疏松药物至关重要。这篇综述讨论了分子靶点及其在疾病进展中的意义、现有的治疗选择、新兴靶点以及设计有效抗骨质疏松药物的重要性。
